[go: up one dir, main page]

AU3958200A - New compounds, their preparation and use - Google Patents

New compounds, their preparation and use

Info

Publication number
AU3958200A
AU3958200A AU39582/00A AU3958200A AU3958200A AU 3958200 A AU3958200 A AU 3958200A AU 39582/00 A AU39582/00 A AU 39582/00A AU 3958200 A AU3958200 A AU 3958200A AU 3958200 A AU3958200 A AU 3958200A
Authority
AU
Australia
Prior art keywords
preparation
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39582/00A
Inventor
Paul Stanley Bury
Lone Jeppesen
Anthony Murray
Ingrid Pettersson
Per Sauerberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU3958200A publication Critical patent/AU3958200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU39582/00A 1999-04-20 2000-04-17 New compounds, their preparation and use Abandoned AU3958200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900532 1999-04-20
DKPA199900532 1999-04-20
PCT/DK2000/000192 WO2000063196A1 (en) 1999-04-20 2000-04-17 New compounds, their preparation and use

Publications (1)

Publication Number Publication Date
AU3958200A true AU3958200A (en) 2000-11-02

Family

ID=8094612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39582/00A Abandoned AU3958200A (en) 1999-04-20 2000-04-17 New compounds, their preparation and use

Country Status (2)

Country Link
AU (1) AU3958200A (en)
WO (1) WO2000063196A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508391A (en) 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド Benzylidene-thiazolidinediones and analogs and their use in treating diabetes
EP1634605A3 (en) 2000-03-08 2006-10-11 Novo Nordisk A/S treatment of dyslipidemia in a patient having type 2 diabetes
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (en) 2001-01-26 2006-10-31 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
EP1377559A4 (en) * 2001-03-08 2005-09-28 Incyte San Diego Inc Rxr activating molecules
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DK1429756T3 (en) 2001-09-21 2007-03-19 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
SE0104334D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
BR0311834A (en) * 2002-06-19 2005-04-12 Lilly Co Eli Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating and preventing diabetes mellitus in a mammal, and for treating syndrome x in a mammal, and, using a compound or pharmaceutically acceptable salt thereof.
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE418551T1 (en) 2003-03-07 2009-01-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
KR20060089874A (en) 2003-09-30 2006-08-09 노보 노르디스크 에이/에스 Novel melanocortin receptor agonists
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PL1723128T3 (en) 2004-01-06 2013-04-30 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2007536344A (en) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ New indole derivatives
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
JP4874989B2 (en) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス Soluble and stable insulin-containing formulation
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
CN103110635A (en) 2005-07-04 2013-05-22 海波因特制药有限责任公司 Histamine H3 receptor antagonist
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
ES2426345T3 (en) 2005-07-20 2013-10-22 Eli Lilly And Company Compound bound in 1-amino position
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
BRPI0618649A2 (en) 2005-11-17 2011-09-06 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a compound
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
ATE538116T1 (en) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-BENYODIOXOL-5-YL)-6-(4-CYCLOPROPYLPIPERAZINE-1-YL)-PYRIDAZINE, ITS SALTS AND SOLVATES AND THEIR USE AS A HISTAMINE H3 RECEPTOR ANTAGONIST
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
CA2669884A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
CA2716352C (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
MX2011003917A (en) 2008-10-15 2011-05-31 Amgen Inc Spirocyclic gpr40 modulators.
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
RU2559320C2 (en) 2010-03-26 2015-08-10 Ново Нордиск А/С Novel glucagon analogues
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
MA49883A (en) 2017-03-15 2021-04-21 Novo Nordisk As BICYCLIC COMPOUNDS SUITABLE TO BIND TO MELANOCORTIN 4 RECEPTOR
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) * 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
WO1993006086A1 (en) * 1991-09-24 1993-04-01 Pfizer Inc. Retinoids and their use in treating skin diseases and leukemia
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0915825B1 (en) * 1996-06-21 2004-05-06 Allergan, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

Also Published As

Publication number Publication date
WO2000063196A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
AU3958100A (en) New compounds, their preparation and use
AU3958200A (en) New compounds, their preparation and use
AU3957900A (en) New compounds, their preparation and use
AU6325599A (en) New compounds, their preparation and use
AU6190199A (en) New compounds, their preparation and use
AU6325799A (en) New compounds, their preparation and use
AU6325899A (en) New compounds, their preparation and use
AU6190299A (en) New compounds, their preparation and use
AU6325699A (en) New compounds, their preparation and use
PL351312A1 (en) New compounds, their preparation and use
AU2001248279A1 (en) New compounds, their preparation and use
AU3956900A (en) Substituted imidazoles, their preparation and use
AU7429100A (en) Chondrocyte compositions, preparation and use thereof
AU3033100A (en) Substituted imidazoles, their preparation and use
EP1072266B8 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
IL138609A0 (en) Antipicornaviral compounds, their preparation and use
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU3595099A (en) New compounds, their preparation and use
AU3159000A (en) Phosphorus-comprising materials, their preparation and use
SI1043307T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU5524400A (en) Novel 6-amino-uracil derivatives, preparation and use thereof
AU2669501A (en) New use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase